Linda Stein Gold, MD: Discussing New Phase 3b Data on Lebrikizumab for Atopic Dermatitis
Stein Gold speaks in this interview about the new lebrikizumab (Ebglyss) data presented at the Fall Clinical Dermatology Conference.
Andrea Murina, MD: Drug Pipeline for Hidradenitis Suppurativa
Murina highlighted takeaways from her seminar-in-depth regarding the evolving therapeutic landscape of HS.
Quan Dong Nguyen, MD: Phase 2 Neptune Trial Advances Brepocitinib for Uveitis
At AAO 2024, Quan Dong Nguyen, MD, and Jia-Horung Hung, MD, discuss the Phase 2 Neptune trial investigating brepocitinib for active non-infectious uveitis.
Omega-3 Supplements for Rosacea and Other Tips for Dermatologists, with Andrea Murina, MD
This discussion with Murina covers several tips for dermatologists to implement, 1 of which touched on omega-3 supplementation for ocular rosacea.
Charles C. Wykoff, MD, PhD: Phase 1b/2a Results on Restoret for DME, nAMD
At AAO 2024, Wykoff discussed first-time extended results from AMARONE showing Restoret’s effectiveness in improving outcomes for patients with DME and nAMD.
Methods to Manage Psoriasis Using Oral Therapies, with Andrea Murina, MD
In her Fall Clinical interview, Murina highlighted several key takeaways related to her talk titled ‘Managing Psoriasis with Oral Therapy: 2024 & Beyond.’
2 Additional Clinical Pearls for Dermatologists, with Eingun James Song, MD
This interview from Fall Clinical covers 2 additional tips for clinical practice as well as unmet needs among patients.
Abdul Abdellatif, MD: Early Osteopenia Interventions Needed for Patients With Kidney Disease and Gout
Abdellatif discussed the importance of screening for osteopenia in patients with severe kidney disease.
Christine N. Kay, MD: TEASE Trials Show Promise of Gildeuretinol for Stargardt
At AAO 2024, Kay presented an overview of gildeuretinol, an oral vitamin A derivative offering hope for patients with Stargardt disease.
Discussing Unmet Needs for Skin Cancer with Laura K. Ferris, MD, PhD, and Neal Bhatia, MD
In this interview at Fall Clinical Dermatology, Ferris and Bhatia highlighted several elements of skin cancer detection and management as well as unmet needs of patients.
Carla Nester, MD: 12-Month Data Informs Potential of Iptacopan in C3 Glomerulopathy
Carla Nester, MD, discusses her perspective on the APPEAR-C3G 12-month data from ASN Kidney Week 2024.
2 Helpful Clinical Tips for Dermatologists, with Eingun James Song, MD
This Fall Clinical Dermatology Conference interview with Song features a discussion regarding several useful clinical pearls for dermatologists.
Collaboration, Intralesional Therapies for Skin Cancer, with Laura K. Ferris, MD, PhD, and Neal Bhatia, MD
This interview features a discussion with Bhatia and Ferris regarding the necessity of collaboration between dermatologists and oncologists for skin cancer.
What Are Some Other Methods To Manage Skin Cancer Outside of Biopsies?
In this interview, Neal Bhatia, MD, and Laura Korb Ferris, MD, PhD, spoke on their Fall Clinical Conference talk titled ‘Beyond the Biopsy: Other Methods To Help Us Manage Skin Cancer.’
New ‘Level Up’ Data on Upadacitinib (Rinvoq) for Atopic Dermatitis, with Christopher Bunick, MD, PhD
This interview with Bunick highlighted the Level Up phase 3b/4 trial findings regarding upadacitinib treatment of patients with atopic dermatitis.
Kidney Compass: Atacicept for IgAN with Jonathan Barratt, MD, PhD, at Kidney Week 2024
Neuen, Wadhwani, and Barratt discuss atacicept promise in IgA nephropathy based on phase 2b ORIGIN OLE results, at-home use, and the future of kidney disease care.
ORIGIN OLE Data Solidify Atacicept Disease-Modifying Potential for IgA Nephropathy
New ORIGIN trial data show atacicept may slow kidney decline in IgA nephropathy to rates seen with healthy aging, with notable reductions in Gd-IgA1 and UPCR.
Julie Refardt, MD, PhD: Current Hyponatremia Clinical Interventions Sufficient
Refardt discussed findings from the largest hyponatremia trial ever conducted, including 2174 participants across 9 European centers.
Richard Pratley, MD: FLOW Mortality Data and Allocation Strategies for Semaglutide
Richard Pratley, MD, discusses how FLOW mortality data informs the use of semaglutide in patients with chronic kidney disease and type 2 diabetes.
Christopher Bunick, MD, PhD: Facts About Systemic Therapies’ Safety, Mechanism of Action
In this interview, Bunick spoke about the contents of his Fall Clinical Dermatology presentation specifically regarding mechanisms of action and safety of systemic therapies.
Shawn Kwatra, MD: Making the Connection Between Prurigo Nodularis, Atopic Dermatitis, and Itch
In this interview, Kwatra highlighted several key takeaways from his talks on prurigo nodularis, atopic dermatitis, and itch at the Fall Clinical Dermatology Conference.
Will Herrington, MBBS, MD, MA: Empagliflozin Follow-up Data Informs Clinical Care for CKD
Herrington shared the carryover effects observed in the post-trial follow-up of the phase 3 EMPA-KIDNEY trial.
Jennifer Lai Yee, MD, PhD, MPH: Honing in on Sparsentan’s Benefit in Genetic FSGS
Yee discussed how the data show a benefit in this hard-to-treat population, similarly to the heterogeneous FSGS group.
Highlighting Recent Therapies for Dermatologists, with James Del Rosso, DO
In this interview segment, Del Rosso highlighted his Fall Clinical presentation takeaways covered in the talk ‘What’s New in the Medicine Chest - Part 2.’
Finerenone Use Reduces UACR, New-Onset Macroalbuminuria in Heart Failure Patients
New FINEARTS-HF data shows that finerenone reduces albuminuria in patients with HFmrEF or HFpEF, but without significant eGFR changes.
Rahul N. Khurana, MD: Phase 1 Results on Vamikibart for Uveitic Macular Edema
At AAO 2024, Khurana discussed rapid visual and structural gains for uveitic macular edema with vamikibart, paving the way for Phase 3 trials.
Sunir J. Garg, MD: Impact of Prior DME Treatment on Aflibercept 8 mg Outcomes
At AAO 2024, Garg describes an analysis of the Phase 2/3 PHOTON trial evaluating the effect of DME treatment history on aflibercept 8 mg and 2 mg outcomes.
James Del Rosso, DO: Discussing What’s New in the Medicine Chest for Dermatologists
In the first part of his Fall Clinical presentation on new topical medications, Del Rosso discusses new therapies available for use among dermatologists.
What To Look Forward To at the Fall Clinical Dermatology Conference, with Raj Chovatiya, MD, PhD
In this interview with Chovatiya, he highlights some of the elements of the presentations being given at the Fall Clinical Dermatology conference in Las Vegas.
Allen C. Ho, MD: Efficacy, Safety of MCO-010 for Retinitis Pigmentosa at 2 Years
At AAO 2024, HO described meaningful BCVA improvements in patients with retinitis pigmentosa observed through 2 years of the Phase 2b/3 RESTORE trial.
